• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[转甲状腺素蛋白淀粉样变性的神经学表现]

[Neurological manifestations of ATTR amyloidosis].

作者信息

Pernice Helena F, Hahn Katrin

机构信息

Amyloidosis Center Charité Berlin (ACCB), Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.

Klinik für Neurologie mit Experimenteller Neurologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.

出版信息

Inn Med (Heidelb). 2023 Sep;64(9):848-854. doi: 10.1007/s00108-023-01570-6. Epub 2023 Aug 9.

DOI:10.1007/s00108-023-01570-6
PMID:37555967
Abstract

Transthyretin amyloidosis (ATTR) is a rare disease in which the protein transthyretin (TTR) is deposited in the form of amyloid fibrils in various tissues and organs and secondarily leads to functional impairment, especially in peripheral nerves and the heart. A differentiation is made between hereditary and sporadic forms. The hereditary variant is inherited in an autosomal dominant manner and usually occurs in the younger to middle-aged, while the sporadic form occurs in older age and has no known genetic cause. Typical signs of hereditary ATTR amyloidosis (ATTRv, v for variant) include a rapidly progressing sensorimotor and autonomic polyneuropathy (PNP), cardiac dysfunction as well as ocular and gastrointestinal symptoms. A carpal tunnel syndrome often precedes the manifestation. Various options (tafamidis, patisiran, inotersen or vutrisiran) are available for the treatment of patients with ATTRv with PNP in Germany, depending on the severity. In the sporadic variant of wild-type ATTR amyloidosis (ATTRwt), symptoms of progressive cardiomyopathy are usually prominent; however, neurological assessment of these patients often also reveals a concomitant sensory ataxic PNP. The tetramer stabilizer tafamidis can be used for treatment. Because of this complex presentation, the management of patients with ATTR amyloidosis should be performed in interdisciplinary centers specialized in amyloidosis.

摘要

转甲状腺素蛋白淀粉样变性(ATTR)是一种罕见疾病,其中转甲状腺素蛋白(TTR)以淀粉样纤维的形式沉积在各种组织和器官中,继而导致功能障碍,尤其是在周围神经和心脏。该病分为遗传性和散发性两种类型。遗传性变异以常染色体显性方式遗传,通常发生在年轻人至中年人中,而散发性类型则发生在老年人中,且无已知的遗传病因。遗传性ATTR淀粉样变性(ATTRv,v代表变异型)的典型症状包括快速进展的感觉运动和自主神经多发性神经病(PNP)、心脏功能障碍以及眼部和胃肠道症状。腕管综合征常先于症状出现。在德国,根据严重程度,有多种治疗方案(他氟米特、帕替沙兰、依诺特森或伏硫西汀)可用于治疗患有PNP的ATTRv患者。在野生型ATTR淀粉样变性(ATTRwt)的散发性变异中,进行性心肌病的症状通常较为突出;然而,对这些患者的神经学评估往往也显示伴有感觉性共济失调性PNP。四聚体稳定剂他氟米特可用于治疗。由于临床表现复杂,ATTR淀粉样变性患者的管理应在专门从事淀粉样变性研究的跨学科中心进行。

相似文献

1
[Neurological manifestations of ATTR amyloidosis].[转甲状腺素蛋白淀粉样变性的神经学表现]
Inn Med (Heidelb). 2023 Sep;64(9):848-854. doi: 10.1007/s00108-023-01570-6. Epub 2023 Aug 9.
2
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.一样又不一样?野生型转甲状腺素蛋白(ATTRwt)淀粉样变的神经表现。
Amyloid. 2022 Jun;29(2):92-101. doi: 10.1080/13506129.2021.2014448. Epub 2022 Jan 7.
3
A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.ATTR 心脏淀粉样变患者的新型药物及临床考虑因素综述
J Cardiovasc Pharmacol. 2021 May 1;77(5):544-548. doi: 10.1097/FJC.0000000000001004.
4
Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.塔非酰胺:一种用于治疗野生型转甲状腺素蛋白淀粉样变性和遗传性转甲状腺素蛋白淀粉样变性心肌病的选择性转甲状腺素蛋白稳定剂。
Drugs Today (Barc). 2019 Dec;55(12):727-734. doi: 10.1358/dot.2019.55.12.3078389.
5
Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.间接治疗比较(ITC)评估 vutrisiran 和 tafamidis 治疗遗传性转甲状腺素淀粉样变多发性神经病的疗效。
Expert Opin Pharmacother. 2023 May-Aug;24(10):1205-1214. doi: 10.1080/14656566.2023.2215925. Epub 2023 May 26.
6
RNA-targeting and gene editing therapies for transthyretin amyloidosis.针对转甲状腺素蛋白淀粉样变性的 RNA 靶向和基因编辑疗法。
Nat Rev Cardiol. 2022 Oct;19(10):655-667. doi: 10.1038/s41569-022-00683-z. Epub 2022 Mar 23.
7
Hereditary Transthyretin Amyloidosis遗传性转甲状腺素蛋白淀粉样变性
8
Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.遗传性转甲状腺素蛋白相关淀粉样变性在无明显病因的多发性神经病和心肌病中较为常见。
Ann Med. 2021 Dec;53(1):1787-1796. doi: 10.1080/07853890.2021.1988696.
9
Therapy of ATTR Cardiac Amyloidosis: Current Indications.转甲状腺素蛋白心脏淀粉样变性的治疗:当前适应症
Curr Probl Cardiol. 2023 Feb;48(2):101487. doi: 10.1016/j.cpcardiol.2022.101487. Epub 2022 Nov 4.
10
Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.由淀粉样前体蛋白转甲状腺素蛋白V122I变体引起的散发性心脏淀粉样变性
Int Heart J. 2019 Nov 30;60(6):1441-1443. doi: 10.1536/ihj.19-134. Epub 2019 Oct 31.

本文引用的文献

1
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis.用于转甲状腺素蛋白淀粉样变性的 RNA 靶向和基因编辑策略。
BioDrugs. 2023 Mar;37(2):127-142. doi: 10.1007/s40259-023-00577-7. Epub 2023 Feb 16.
2
Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages.皮肤淀粉样变是早期转甲状腺素蛋白淀粉样变多发性神经病的生物标志物,并在疾病各阶段进展。
Ann Clin Transl Neurol. 2022 Sep;9(9):1370-1383. doi: 10.1002/acn3.51636. Epub 2022 Aug 9.
3
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis.
ATTRv 淀粉样变治疗和监测的指南和新方向。
Amyloid. 2022 Sep;29(3):143-155. doi: 10.1080/13506129.2022.2052838. Epub 2022 Jun 2.
4
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).转甲状腺素蛋白淀粉样变性心肌病患者自主神经功能障碍特征分析(THAOS)。
Amyloid. 2022 Sep;29(3):175-183. doi: 10.1080/13506129.2022.2043270. Epub 2022 Apr 22.
5
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.遗传性转甲状腺素蛋白淀粉样变性的神经表现:关注诊断延迟。
Amyloid. 2022 Sep;29(3):184-189. doi: 10.1080/13506129.2022.2046557. Epub 2022 Mar 7.
6
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.一样又不一样?野生型转甲状腺素蛋白(ATTRwt)淀粉样变的神经表现。
Amyloid. 2022 Jun;29(2):92-101. doi: 10.1080/13506129.2021.2014448. Epub 2022 Jan 7.
7
Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis.我们正在创造一种新的表型吗?遗传性转甲状腺素蛋白淀粉样变性治疗中的生理屏障与伦理考量。
Neurol Res Pract. 2021 Nov 1;3(1):57. doi: 10.1186/s42466-021-00155-8.
8
Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.混合队列 ATTR-淀粉样变中大、小神经纤维损伤的临床和仪器研究:对患者管理的影响及野生型的新见解。
Amyloid. 2022 Mar;29(1):14-22. doi: 10.1080/13506129.2021.1976751. Epub 2021 Oct 11.
9
Current Review of Leptomeningeal Amyloidosis Associated With Transthyretin Mutations.当前对转甲状腺素蛋白突变相关脑脊髓液淀粉样变性的综述。
Neurologist. 2021 Sep 7;26(5):189-195. doi: 10.1097/NRL.0000000000000337.
10
The neuropathy in hereditary transthyretin amyloidosis: A narrative review.遗传性转甲状腺素蛋白淀粉样变性神经病:叙述性综述。
J Peripher Nerv Syst. 2021 Jun;26(2):155-159. doi: 10.1111/jns.12451. Epub 2021 May 11.